The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors

Abstract Background Treatment with immune checkpoint inhibitors (ICIs) targeting CTLA-4 and the PD-1/PD-L1 axis is effective against many cancer types. However, due in part to unresponsiveness or acquired resistance, not all patients experience a durable response to ICIs. HBI-8000 is a novel, orally...

Full description

Bibliographic Details
Main Authors: Reid P. Bissonnette, Rosemary M. Cesario, Bob Goodenow, Farbod Shojaei, Mireille Gillings
Format: Article
Language:English
Published: BMC 2021-08-01
Series:BMC Cancer
Subjects:
Histone deacetylase
HDAC
Epigenetics
PD-1
PD-L1
Immune checkpoint
Online Access:https://doi.org/10.1186/s12885-021-08702-x

Internet

https://doi.org/10.1186/s12885-021-08702-x

Similar Items